Dr. Patil on the Development of KRAS G12C Inhibitors in Lung Cancer


In Partnership With:

Pradnya D. Patil, MD, FACP, discusses the development of KRAS G12C inhibitors in lung cancer.

Pradnya D. Patil, MD, FACP, Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, discusses the development of KRAS G12C inhibitors in lung cancer.

KRAS mutations were identified in lung cancer decades ago; however, developing a targeted therapy against the RAS pathway has been difficult, Patil explains. Significant research led to the development of the KRAS G12C inhibitors sotorasib (Lumakras) and adagrasib (MRTX849). Sotorasib was approved by the FDA on May 28, 2021, for use as first-line treatment of patients with non–small cell lung cancer whose tumors harbor KRAS G12C mutations and who have received at least 1 prior systemic therapy.

Unlike TKIs, KRAS G12C inhibitors are allele specific, which could account for the numerically modest response rates demonstrated by the agents, Patil says. However, these agents offer a novel class of drugs to this specific patient population that has historically been very challenging to treat, Patil concludes.

Related Videos
Ariel Grajales-Cruz, MD
Nikhil A. Gopal, MD
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine